{'fraction_non_alphanumeric': 0.027659574468085105, 'fraction_numerical': 0.012056737588652482, 'mean_word_length': 5.442922374429224, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A number of the N-terminal RASSF family: RASSF7.

The Ras association domain family 7 (RASSF7, also named HRC1), a potential tumor related gene, which is located on human chromosome 11p15, has been identified as an important member of N-terminal RASSF family. Whereas, the molecular biological mechanisms of RASSF7 in tumorigenesis remain to be further established. We perform a systematic review of the literature and assessment from PUBMED and MEDLINE databases in this article. RASSF7 plays a significant role in mitosis, microtubule growth, apoptosis, proliferation and differentiation. Many researching literature show that RASSF7 could promote the occurrence and advance of human tumors by regulating Aurora B, MKK4, MKK7, JNK, YAP, MEK, ERK, whereas, it might inhibit c-Myc and thus lead to the suppression of tumorigenesis. Upregulation of RASSF7 often occur in various malignancies such as lung cancer, neuroblastoma, thyroid neoplasm, hepatocellular cancer, breast cancer and gastric cancer. The expression stage of RASSF7 is positively correlated with tumor TNM stage. In this review, we primarily elaborate the acknowledged structure, progress in the various biomechanisms and research advance of RASSF7 especially the potential relevant signaling pathways. We hope that RASSF7 as a prospective therapeutic target for human malignancies could play an available role in future anti-cancer treatment.